to give patients and their
families more bluebird days.
Setting the standard for gene therapy
Gene Addition Therapy: We’re building platforms with broad therapeutic potential because incremental improvements won’t do
Delivering more bluebird days for patients and their families requires a different approach to treating disease. In a rapidly advancing field, we’ve been leading the way for a decade. At bluebird, our proprietary lentiviral vector gene therapies are one-time treatments that are designed to deliver a functional copy of a gene to a patient’s own cells.
bluebird bio, Inc. gene therapies are investigational and not FDA-approved. Safety and efficacy have not been established.
Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019;9:297.
Negre O, Eggimann A-V, Beuzard Y, et al. Gene therapy of the β-hemoglobinopathies by lentiviral transfer of the βA(T87Q)-globin gene. Hum Gene Ther. 2016;27:148-165.
National Institutes of Health. Genetics Home Reference. Help me understand genetics. Available at: https://medlineplus.gov/download/genetics/understanding/primer.pdf. Accessed April 2022.